ObjectiveTo explore risk factors of blood transfusion during liver transplantation and construct its prediction model. MethodsThe patients underwent liver transplantation who met the inclusion and exclusion criteria of this study from March 2020 to December 2020 in the Beijing Youan Hospital of Capital Medical University were retrospectively collected. The univariate and logistic multivariate analysis were used to evaluate the risk factors of blood transfusion during liver transplantation and construct the prediction model for intraoperative blood transfusion. ResultsA total of 151 eligible liver transplantation patients were collected in this study, including 51 non-transfusion patients and 100 transfusion patients. The univariate analysis results showed that the differences of primary diagnosis, preoperative hemoglobin (Hb), platelet count, prothrombin time, international normalized ratio, Child-Turcotte-Pugh score, and end-stage liver disease (MELD) score were statistically different between them (P<0.05). The above variables selected by the univariate analysis were selected by stepwise method, then the preoperative Hb and MELD score were selected into the multivariate logistic regression analysis, the results showed that the preoperative Hb≤113 g/L and MELD score >14 increased the risk of blood transfusion during liver transplantation [Hb: OR=6.652, 95%CI (2.282, 19.392), P<0.001; MELD score: OR=16.037, 95%CI (6.336, 40.592), P<0.001]. The logistic regression model predicted the area under receiver operating characteristic curve was 0.873 [95%CI (0.808, 0.919), P<0.001], the sensitivity and specificity were 91.0% and 67.5%, respectively, Youden index was 0.674, the accuracy was 86.1%. ConclusionsResults of this study suggest that preoperative Hb ≤113 g/L and MELD score>14 increase risk of blood transfusion during liver transplantation. Logistic regression model constructed according to preoperative Hb and MELD score has a better sensitivity and specificity of intraoperative blood transfusion.
Objective To evaluate the therapeutic effect of selective paraesophagogastric devascularization withoutsplenectomy in treatment of portal hypertension with upper gastrointestinal hemorrhage. Methods The clinical data of 27 patients who received selective paraesophagogastric devascularization without splenectomy from 2008 to 2011 were retrospectively analyzed. The hemogram, hepatic function, perioperative compliations, and free portal pressure (FPP) were observed. The patients were followed-up and the re-bleeding rate and survival rate were observed. Results The FPP decreased significantly(P<0.05) after operation. The complication rate was 33.3%(9/27) after operation, including2 cases(7.4%) stress ulcer bleeding, 1 case (3.7%) acute bleeding portal hypertensive gastropathy, 1 case (3.7%) deep venous thrombosis, 1 case (3.7%) acute lung injury, 1 case (3.7%) death of hepatic encephalopathy, 3 cases(11.1%) new onset portal vein thrombosis. Twenty-four patients were followed up for an average of 27 months (8-57 months). The overal survival rate was 92.6% (25/27). Conclusion Selective paraesophagogastric devascularization without splenectomy is an effective method for treatment of portal hypertension with upper gastrointestinal hemorrhage.
【摘要】 目的 探讨后程适形放射治疗(3 dimensional comformal radiation therapy,3D-CRT)同步化学疗法治疗Ⅲ期非小细胞肺癌(non-small-cell lung cancer,NSCLC)的近期疗效。 方法 搜集2005年1月-2008年6月NSCLC患者共115例,其中53例行单纯后程3D-CRT(单放组),62例行后程3D-CRT联合同步化学疗法(联合组),所有患者均经病理证实为Ⅲ期NSCLC。两组放射治疗方案均采用常规分割治疗加后程3D-CRT,DT 62~72 Gy。联合组化学疗法采用TP(紫杉醇 + 顺铂)方案。 结果 单放组和联合组近期疗效(完全缓解+部分缓解)分别为75.47%、91.94%,差异有统计学意义(Plt;0.05)。单放组和联合组的治疗不良反应主要有白细胞、血小板减少,放射性食管炎,放射性气管炎,恶心、呕吐等胃肠道反应。骨髓抑制和消化道反应,联合组稍高于单放组。经对症治疗后,所有患者均可耐受。 结论 后程3D-CRT联合TP方案化学疗法较单纯后程适形放射治疗明显提高Ⅲ期NSCLC近期疗效。患者耐受性尚可。【Abstract】 Objective To observe the recent therapeutic effect of late course 3 dimensional conformal therapy concomitant with chemotherapy on locally advanced stage Ⅲ non-small-cell lung cancer (NSCLC). Methods From January 2005 to June 2008, 115 patients with stage Ⅲ NSCLC were confirmed by pathology, in whom 53 only underwent late course conformal therapy (radiotherapy group), and another 62 underwent late course conformal therapy concomitant with chemotherapy (combined group). The radiotherapy schema of the two groups was routine division plus late course conformal therapy (with DT 62-72 Gy). The chemotherapy schema in the combined group was performed with TP (paclitaxel and DDP). Results The recent curative effect (complete remission plus partial remission) in radiotherapy group and combined group was 75.47% and 91.94%, respectively (Plt;0.05). The frequent adverse reactions in the two groups included leucocytopenia, thrombocytopenia, radioactive esophagitis, radioactive tracheitis, nauseated, and emesia. The rate of bone marrow depression and alimentary canal reaction in combined group was higher than that in the radiotherapy group. In the two groups, all patients could tolerance the treatments. Conclusion Late course 3 dimensional conformal therapy concomitant with TP schema chemotherapy for NSCLC could raise the recent curative effect. The patients could tolerance the treatments.
【摘要】 目的 剪切修复偶联因子1(ERCC1)是核苷酸外切修复家族中的重要成员,它在核酸损伤修复过程和凋亡过程中起着重要作用;存活蛋白(Survivin)属凋亡抑制蛋白家族,是迄今发现的最强的凋亡抑制因子之一。研究中初步探索晚期非小细胞肺癌(non-small-cell lung cancer,NSCLC)中ERCC1和Survivin与铂类化学疗法敏感性的关系及其相关性。 方法 2001年1月-2002年6月对51例晚期NSCLC(ⅢB或Ⅳ期)标本经免疫组织化学检测ERCC1和Survivin的表达,患者行至少2周期含铂方案化学疗法,2周期化学疗法后评价疗效,采用SPSS 13.0软件就检测指标和化学疗法疗效评价进行相关统计分析。 结果 ERCC1和Survivin在肿瘤组织中阳性表达率分别为58.8 %(30/51)和76.5 %(39/51)。ERCC1阴性组化学疗法有效率高于阳性组(Plt;0.05),5年生存时间高于阳性组(Plt;0.05);Survivin阴性组化学疗法有效率虽高于阳性组,但无统计学意义(Pgt;0.05),其5年生存时间与阴性组比较无差别(Pgt;0.05)。Spearman相关分析提示ERCC1与Survivin之间无相关性(rs=-0.088,P=0.537)。 结论 ERCC1和Survivin可能与NSCLC的发生相关,ERCC1可能与肿瘤的预后相关,并对化学疗法疗效具有一定预测价值。ERCC1和Survivin之间耐药机制可能各不相同。【Abstract】 Objective Excision repair cross-complementing 1 (ERCC1), an important member of the DNA repair gene family, plays a key role in nucleotide excision repair and apoptosis of tumor cells. Survivin, a member of inhibitor of apoptosis protein (IAP) family, is one of the most powerful factors in inhibiting apoptosis up to now. This study is to explore the value of ERCC1 and Survivin in predicting the sensitivity of non-small cell lung cancer (NSCLC) to platinum-based chemotherapy and the interrelationship between the two markers. Methods From January 2001 to June 2002, expressions of ERCC1 and Survivin of 51 advanced NSCLC patients (Ⅲ B or IV) were tested through immunohistochemistry. The patients were treated with at least 2 cycles of platinum-based chemotherapy. The curative effect was evaluated later, and the relationship among detected data, curative effect of chemotherapy and patients′ clinical parameters were analyzed with SPSS 13.0 software. Results The positive expression rates of ERCC1 and Survivin in NSCLC tissues were 58.8 % (30/51) and 76.5 % (39/51), respectively. The effective rate of chemotherapy and 5-year survival rate for the negative group of ERCC1 were significantly higher than those for the positive group (Plt;0.05). The results for Survivin were similar to those for ERCC1, but there was no statistical significance (Pgt;0.05). We also found there was no relationship between ERCC1 and Survivin by Spearman′s correlation analysis (rs=-0.088, P=0.537). Conclusion ERCC1 and Survivin may be correlated with the development of NSCLC, and ERCC1 may be related to curative effect and prognosis of NSCLC. There was probably no mechanism of coordination or regulation in multi-drug resistance between ERCC1 and Survivin.
目的 观察消化道肿瘤患者服用甲羟孕酮(medroxyprogesterone acetate, MPA)对化疗后骨髓抑制的影响。 方法 2008年11月-2009年8月,将接受化疗的消化道肿瘤患者共100例随机分为治疗组(MPA加化疗组,54例)及对照组(单纯化疗组,46例),2周期化疗后评价骨髓抑制状况和生活质量变化。 结果 治疗组和对照组化疗后白细胞、血红蛋白和血小板Ⅰ~Ⅱ度骨髓抑制发生率没有差异(Pgt;0.05),但治疗组Ⅲ~Ⅳ度骨髓抑制发生率低于对照组,KPS评分改善率高于对照组(Plt;0.05)。未见明显不良反应。 结论 MPA可有效减轻化疗后骨髓抑制。